We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Revolutionary Blood Test to Transform Early Diagnosis of Bowel Cancer

By LabMedica International staff writers
Posted on 20 May 2022

Bowel (colorectal) cancer is the second most common cancer globally. More...

It is the leading cause of cancer-related death in the Western world. Early diagnosis of bowel cancer significantly reduces mortality rate. Current diagnostics tests such as colonoscopy or fecal blood detection kits can be invasive, unpleasant and expensive. Now, an accurate, non-invasive, inexpensive blood test can diagnose bowel cancer early and dramatically cut waiting times for diagnosis while reducing the need for unnecessary invasive procedures such as colonoscopies.

Researchers at Swansea University (Swansea, UK) have devised a simple Raman Spectrometry (RS) blood test which can return test results in under 20 minutes. Using innovations based around laser spectroscopy and artificial intelligence (AI) -based analytics, the test analyses cancer-driven metabolic activity in blood that their AI software is trained to interpret and diagnose. The test aims to break down patient anxiety with a highly accurate test to give rapid reassurance to those who have not got cancer and ensure they do not need an invasive colonoscopy. As a result, this will free up valuable endoscopy and colonoscopy resource and speed up treatment for those who have cancer while resulting in savings from a reduction of needless colonoscopies.

Results from a ground-breaking study involving 27 practices and 595 patients showed 79% of early-stage bowel cancers and 100% of advanced bowel cancers were picked up by the test. Early comparisons with other tests currently available in primary care have shown the RS blood test to have greater sensitivity for the detection of bowel cancer. Currently, a high number of unnecessary colonoscopies are conducted to ensure cases of bowel cancer are detected. Since the start of the pandemic, waiting lists for the procedure have significantly increased. These delays can reduce the chances of patient survival, with many people being diagnosed too late. The blood test hopes to change all that by providing accurate results within 48 hours, preventing unnecessary colonoscopies and relieving pressure on healthcare systems.

Related Links:
Swansea University 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
POC Immunoassay Analyzer
Procise DX
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.